120 related articles for article (PubMed ID: 20030297)
1. Computational study of the interactions between guanine derivatives and cyclin-dependent kinase 2 (CDK2) by CoMFA and QM/MM.
Alzate-Morales J; Caballero J
J Chem Inf Model; 2010 Jan; 50(1):110-22. PubMed ID: 20030297
[TBL] [Abstract][Full Text] [Related]
2. Mapping the binding site of a large set of quinazoline type EGF-R inhibitors using molecular field analyses and molecular docking studies.
Hou T; Zhu L; Chen L; Xu X
J Chem Inf Comput Sci; 2003; 43(1):273-87. PubMed ID: 12546563
[TBL] [Abstract][Full Text] [Related]
3. Comparative molecular field analysis of flavonoid inhibitors of the PIM-1 kinase.
Holder S; Lilly M; Brown ML
Bioorg Med Chem; 2007 Oct; 15(19):6463-73. PubMed ID: 17637507
[TBL] [Abstract][Full Text] [Related]
4. Quantitative structure-activity relationship of organosulphur compounds as soybean 15-lipoxygenase inhibitors using CoMFA and CoMSIA.
Caballero J; Fernández M; Coll D
Chem Biol Drug Des; 2010 Dec; 76(6):511-7. PubMed ID: 21040497
[TBL] [Abstract][Full Text] [Related]
5. Insights into the structural basis of N2 and O6 substituted guanine derivatives as cyclin-dependent kinase 2 (CDK2) inhibitors: prediction of the binding modes and potency of the inhibitors by docking and ONIOM calculations.
Alzate-Morales JH; Caballero J; Vergara Jague A; González Nilo FD
J Chem Inf Model; 2009 Apr; 49(4):886-99. PubMed ID: 19323453
[TBL] [Abstract][Full Text] [Related]
6. 3D-QSAR and molecular docking study on bisarylmaleimide series as glycogen synthase kinase 3, cyclin dependent kinase 2 and cyclin dependent kinase 4 inhibitors: an insight into the criteria for selectivity.
Dessalew N; Bharatam PV
Eur J Med Chem; 2007 Jul; 42(7):1014-27. PubMed ID: 17335939
[TBL] [Abstract][Full Text] [Related]
7. Molecular Modeling and Design Studies of Purine Derivatives as Novel CDK2 Inhibitors.
Zhang G; Ren Y
Molecules; 2018 Nov; 23(11):. PubMed ID: 30423939
[TBL] [Abstract][Full Text] [Related]
8. Protein structures in virtual screening: a case study with CDK2.
Thomas MP; McInnes C; Fischer PM
J Med Chem; 2006 Jan; 49(1):92-104. PubMed ID: 16392795
[TBL] [Abstract][Full Text] [Related]
9. An in silico exploration of the interaction mechanism of pyrazolo[1,5-a]pyrimidine type CDK2 inhibitors.
Li Y; Gao W; Li F; Wang J; Zhang J; Yang Y; Zhang S; Yang L
Mol Biosyst; 2013 Sep; 9(9):2266-81. PubMed ID: 23864105
[TBL] [Abstract][Full Text] [Related]
10. Molecular modeling studies to characterize N-phenylpyrimidin-2-amine selectivity for CDK2 and CDK4 through 3D-QSAR and molecular dynamics simulations.
Chohan TA; Chen JJ; Qian HY; Pan YL; Chen JZ
Mol Biosyst; 2016 Apr; 12(4):1250-68. PubMed ID: 26883408
[TBL] [Abstract][Full Text] [Related]
11. Study of differences in the VEGFR2 inhibitory activities between semaxanib and SU5205 using 3D-QSAR, docking, and molecular dynamics simulations.
Muñoz C; Adasme F; Alzate-Morales JH; Vergara-Jaque A; Kniess T; Caballero J
J Mol Graph Model; 2012 Feb; 32():39-48. PubMed ID: 22070999
[TBL] [Abstract][Full Text] [Related]
12. 3D-QSAR analysis on benzazole derivatives as eukaryotic topoisomerase II inhibitors by using comparative molecular field analysis method.
Temiz-Arpaci O; Tekiner-Gulbas B; Yildiz I; Aki-Sener E; Yalcin I
Bioorg Med Chem; 2005 Dec; 13(23):6354-9. PubMed ID: 15993083
[TBL] [Abstract][Full Text] [Related]
13. Insights into the structure of urea-like compounds as inhibitors of the juvenile hormone epoxide hydrolase (JHEH) of the tobacco hornworm Manduca sexta: analysis of the binding modes and structure-activity relationships of the inhibitors by docking and CoMFA calculations.
Garriga M; Caballero J
Chemosphere; 2011 Mar; 82(11):1604-13. PubMed ID: 21134691
[TBL] [Abstract][Full Text] [Related]
14. 3D-QSAR of human immunodeficiency virus (I) protease inhibitors. III. Interpretation of CoMFA results.
Opera TI; Waller CL; Marshall GR
Drug Des Discov; 1994 Jul; 12(1):29-51. PubMed ID: 7578806
[TBL] [Abstract][Full Text] [Related]
15. Why pyridine containing pyrido[2,3-d]pyrimidin-7-ones selectively inhibit CDK4 than CDK2: insights from molecular dynamics simulation.
Mascarenhas NM; Bhattacharyya D; Ghoshal N
J Mol Graph Model; 2010 Apr; 28(7):695-706. PubMed ID: 20153225
[TBL] [Abstract][Full Text] [Related]
16. Comparative molecular field analysis of hydantoin binding to the neuronal voltage-dependent sodium channel.
Brown ML; Zha CC; Van Dyke CC; Brown GB; Brouillette WJ
J Med Chem; 1999 May; 42(9):1537-45. PubMed ID: 10229624
[TBL] [Abstract][Full Text] [Related]
17. Three-dimensional quantitative structure: activity relationship studies on diverse structural classes of HIV-1 integrase inhibitors using CoMFA and CoMSIA.
Nunthaboot N; Tonmunphean S; Parasuk V; Wolschann P; Kokpol S
Eur J Med Chem; 2006 Dec; 41(12):1359-72. PubMed ID: 17002889
[TBL] [Abstract][Full Text] [Related]
18. 3D-QSAR CoMFA study on indenopyrazole derivatives as cyclin dependent kinase 4 (CDK4) and cyclin dependent kinase 2 (CDK2) inhibitors.
Singh SK; Dessalew N; Bharatam PV
Eur J Med Chem; 2006 Nov; 41(11):1310-9. PubMed ID: 16890327
[TBL] [Abstract][Full Text] [Related]
19. A computational model of binding thermodynamics: the design of cyclin-dependent kinase 2 inhibitors.
Sims PA; Wong CF; McCammon JA
J Med Chem; 2003 Jul; 46(15):3314-25. PubMed ID: 12852762
[TBL] [Abstract][Full Text] [Related]
20. CoMFA and docking studies on triazolopyridine oxazole derivatives as p38 MAP kinase inhibitors.
Shashi Nayana MR; Sekhar YN; Siva Kumari N; Mahmood SK; Ravikumar M
Eur J Med Chem; 2008 Jun; 43(6):1261-9. PubMed ID: 17825954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]